Search Results

The C. DIFF QUIK CHEK COMPLETE™ test is a rapid membrane enzyme immunoassay for the simultaneous detection of Clostridium difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test detects C. difficile antigen, glutamate dehydrogenase, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease. The test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history. FOR IN VITRO DIAGNOSTIC USE.

The C. DIFF QUIK CHEK COMPLETE™ test uses antibodies specific for qlutamate dehydrogenase (GDH) and Toxins A and B of C. difficile. The device contains a Reaction Window with two solid lines and a dotted line of immobilized antibodies. The Antigen line ("Ag") contains antibodies against C. difficile GDH. The Toxin line ("Tox") contains antibodies against C. difficile toxins A and B. The dotted line, representing a control line ("C"), contains anti-HRP antibodies. The Conjugate consists of antibodies to GDH, toxin A, and toxin B coupled to horseradish peroxidase. To perform the test, the fecal specimen is diluted with Diluent, and Conjugate is added to the diluted sample. The diluted sample-conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, any GDH, toxin A or toxin B in the sample binds to the corresponding antibody-peroxidase conjugate. The antigen-antibody complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-GDH, anti-toxin A or Anti-toxin B antibody in the line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After a 10-minute incubation, the "Ag" and "Tox" reaction is examined visually for the appearance of a blue line. A blue line indicates a positive test. A positive "C" reaction, indicated by a blue dotted line, confirms that sample and all reagents were added in proper sequence and volume, that reagents were active at the time of performing the assay, and that proper sample migration occurred.

Here's a breakdown of the acceptance criteria and the study details for the C. DIFF QUIK CHEK COMPLETE™ device, based on the provided text:

Acceptance Criteria and Reported Device Performance

The document provides performance metrics rather than explicitly stated "acceptance criteria" in the format of pass/fail thresholds. However, the reported performance data can be interpreted as the device meeting the implicit acceptance criteria by demonstrating adequate clinical accuracy compared to established reference methods.

Study Information

1. Sample Size Used for the Test Set and Data Provenance:

   • Test Set Sample Size: n = 1126 clinical samples.
   • Data Provenance: The study was conducted at 3 clinical sites. The document does not specify the country of origin, but given the FDA 510(k) submission, it is highly likely to be within the United States. The nature of comparing with "tissue culture assay" and "bacterial culture" suggests these are prospectively collected clinical samples, though the document does not explicitly state "prospective" or "retrospective." However, the wording "results from all 3 clinical sites are included in the summary" typically indicates a prospective collection for a clinical trial or evaluation.

2. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
   The document does not provide details on the number or qualifications of experts. However, the ground truth was established by laboratory methods (bacterial culture and tissue culture assay) and further resolved by commercial ELISA tests. These methods are typically performed by trained laboratory personnel.

3. Adjudication Method for the Test Set:

   • GDH Antigen: Discrepant samples between the C. DIFF QUIK CHEK COMPLETE™ test and bacterial culture were resolved using the C. DIFFICILE CHEK™ - 60 ELISA (which detects GDH antigen).
   • Toxins A and B: Discrepant results between the C. DIFF QUIK CHEK COMPLETE™ test and tissue culture assay were analyzed by either the C. DIFFICILE TOX A/B I/™ test or a "second commercially available Toxin A&B test."

4. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, What was the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance:
   This device is a rapid membrane enzyme immunoassay (a diagnostic test kit), not an AI-powered image analysis or diagnostic system. Therefore, an MRMC comparative effectiveness study involving human readers with/without AI assistance is not applicable to this device. The results are read visually for the appearance of a blue line, which is a direct interpretation of the assay's chemical reaction, not a complex image requiring human expert interpretation in the way AI systems are typically evaluated in MRMC studies.

5. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done:
   Yes, a standalone performance was done. The results presented for sensitivity, specificity, predictive values, and agreement are directly comparing the device's output (positive/negative blue line) to the ground truth established by the reference methods (bacterial culture and tissue culture assay). There is no explicit "human-in-the-loop" aspect being evaluated in these performance metrics beyond the visual reading of the test result itself, which is integral to the device's function.

6. The Type of Ground Truth Used:

   • For GDH antigen:
     • Primary reference: Bacterial Culture (for overall presence of C. difficile organism).
     • Secondary/Discrepant resolution: C. DIFFICILE CHEK™ - 60 ELISA (an established GDH antigen detection assay).
     • A separate comparison was also made against Tissue Culture Assay (presumably for toxigenic C. difficile, as it usually detects toxin production), specifically looking at the GDH antigen portion of the C. DIFF QUIK CHEK COMPLETE™.
   • For Toxins A and B:
     • Primary reference: Tissue Culture Assay (the gold standard for detecting toxigenic C. difficile).
     • Secondary/Discrepant resolution: C. DIFFICILE TOX A/B I/™ test or a "second commercially available Toxin A&B test."

7. The Sample Size for the Training Set:
   The document does not specify a separate "training set" size for the clinical accuracy evaluation. The n=1126 samples are referred to as the clinical performance evaluation set. This device is an immunoassay kit, which typically does not involve machine learning or AI algorithms that require distinct training and test sets in the same manner as software devices. Any "training" would have been part of the assay development and optimization phases, not explicitly quantified as a clinical "training set" in this context.

8. How the Ground Truth for the Training Set Was Established:
   As there's no explicitly defined "training set" in the context of clinical accuracy for this type of device mentioned in the document, this question is not directly applicable. The methods used to establish ground truth for the evaluation set (bacterial culture and tissue culture assay with ELISA for discrepancy resolution) would be the standard reference methods used in the development and validation of similar assays.

Ask a specific question about this device

The C. DIFF QUIK CHEK™ test is a rapid membrane enzyme immunoassay for use as a screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile disease. The test does not distinguish toxigenic from nontoxigenic strains of C. difficile. With the use of additional tests that detect C. difficile toxins, the test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history. FOR IN VITRO DIAGNOSTIC USE.

The C. DIFF QUIK CHEK™ test uses antibodies specific for glutamate dehydrogenase (GDH) of C. difficile. The device contains a Reaction Window with two lines of immobilized antibodies. The test line ("T") contains antibodies against C. difficile GDH. The other, representing a control line ("C"), contains anti-IgG antibodies. The Conjugate consists of antibody to GDH coupled to horseradish peroxidase. To perform the test, the fecal specimen is diluted with Diluent, and Conjugate is added to the diluted sample. The diluted sample conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, any GDH in the sample binds to antibodyperoxidase conjugate. The antigen-antibody complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-GDH antibody in the line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After up to a 10-minute incubation, the "T" reaction is examined visually for the appearance of a blue line indicates a positive test. A positive "C" reaction, indicated by a blue line, confirms that sample and all reagents were added in proper sequence and volume, that reagents were active at the time of performing the assay, and that proper sample migration occurred.

Here's a summary of the acceptance criteria and the study that proves the device meets them, based on the provided text:

Device: C. DIFF QUIK CHEK™ test

Intended Use: A rapid membrane enzyme immunoassay for use as a screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile disease. The test does not distinguish toxigenic from nontoxigenic strains of C. difficile. With the use of additional tests that detect C. difficile toxins, the test is to be used as an aid in the diagnosis of C. difficile disease. Results should be considered in conjunction with the patient history.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are not explicitly stated as numerical targets in the document. However, the study aims to demonstrate substantial equivalence to previously cleared devices and clinical correlation. Based on the "Clinical Performance Comparing C. DIFF QUIK CHEK™ Test to Presumptive Bacterial Culture" table and the "Clinical Performance of C. DIFF QUIK CHEK™ Test versus Bacterial Culture Assay after Resolution by another GDH Test" table, the implied acceptance range would be within the 95% Confidence Limits of the reported performance metrics.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: 979 fecal specimens.
• Data Provenance: The document states that "Results from 3 studies are included in the summary," and the protocols are in Appendix A and D. It does not specify the country of origin of the data or whether it was retrospective or prospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

The document does not explicitly state the number or qualifications of experts used to establish initial ground truth. The primary comparator was "Presumptive Bacterial Culture."

4. Adjudication Method for the Test Set

The document describes an adjudication method for discrepant samples:

• "The discrepant samples generated from the C. DIFF QUIK CHEK™ test and the presumptive bacterial culture assay were resolved using a PCR assay, an ELISA for the antigen, or a membrane test for the antigen, as described in the individual studies."
• This indicates a "discrepant analysis" approach, where discrepancies between the index test (C. DIFF QUIK CHEK) and the initial comparator (presumptive bacterial culture) were sent for re-evaluation using one or more additional, often more sensitive or specific, methods (PCR, ELISA, membrane test).

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, a multi-reader, multi-case (MRMC) comparative effectiveness study was not done. This device is an in-vitro diagnostic test (a rapid membrane enzyme immunoassay) and not an AI-assisted diagnostic tool designed to aid human readers in interpreting images or other complex data. Therefore, the concept of human readers improving with AI assistance does not apply.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, a standalone performance study was done. The C. DIFF QUIK CHEK™ test is presented as a standalone diagnostic device, where the visual interpretation of a distinct blue line (or lack thereof) is the final output. The performance metrics (sensitivity, specificity, etc.) presented are for the device operating independently.

7. The Type of Ground Truth Used

The primary initial ground truth was presumptive bacterial culture (Clostridium difficile Culture media such as cycloserine cefoxitin fructose agar (CCFA)).

For discrepant results, the refined ground truth was established using consensus or advanced methods including:

• PCR assay
• ELISA for the antigen
• Another membrane test for the antigen

This is a form of resolved gold standard, where a more definitive test is used to resolve disagreements between the index test and the initial comparator.

8. The Sample Size for the Training Set

The document does not provide information regarding a specific "training set" or its sample size. This type of regulatory submission (510(k)) for an in-vitro diagnostic typically focuses on clinical validation of the final device, rather than the developmental or training phases that might involve machine learning algorithms. The development of an immunoassay involves laboratory optimization and verification, but not typically a "training set" in the context of AI.

9. How the Ground Truth for the Training Set was Established

As no specific training set information is provided, how its ground truth was established is not applicable and not described in this document.

Ask a specific question about this device